FOLH1 and posterior cortical atrophy: Even if PET/CT with the other radiotracers mentioned above is also able to detect bone metastases, potentially with even greater sensitivity than 18F-NaF PET/CT (e.g., PET/CT with PSMA-targeted agents may detect lesions in bone marrow even before associated lesions of the bone matrix), the use of 18F-NaF PET/CT in the detection of bone metastases in PCa generally represents a clinical application in patients with far more advanced disease than biochemical recurrence [4,37].